The most physiological way to reach a normal level of glycaemia.
The only route to bring cell therapy to reality in a safe manner.
Primordial to guarantee long term cell survival and function.
A bioartificial pancreas to treat type 1 diabetes: optimization of cell survival and function in preclinical and clinical phases.
MAILPAN® (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients. The prototype was developed along different stages since 1996 and led to the creation of the SME called Defymed in 2011.